Provided by Tiger Trade Technology Pte. Ltd.

Quest Diagnostics

231.45
-4.0100-1.70%
Volume:311.28K
Turnover:72.40M
Market Cap:25.55B
PE:24.58
High:236.48
Open:236.48
Low:230.84
Close:235.46
52wk High:247.19
52wk Low:171.18
Shares:110.37M
Float Shares:110.00M
Volume Ratio:0.83
T/O Rate:0.28%
Dividend:3.32
Dividend Rate:1.43%
EPS(TTM):9.42
EPS(LYR):8.75
ROE:14.60%
ROA:6.40%
PB:3.40
PE(LYR):26.45

Loading ...

Quest Diagnostics Expands Oncology Testing Access Via Flatiron Health's OncoEMR MPI

MT Newswires Live
·
Jul 08

Quest Diagnostics Integrates Oncology Testing into Flatiron Oncoemr Via Pilot with American Oncology Network

Reuters
·
Jul 08

Quest Diagnostics Inc. Stock Outperforms Competitors Despite Losses on the Day

Dow Jones
·
Jul 07

Quest Diagnostics (DGX) Could Be 4% Undervalued On Haystack MRD Approval

Simply Wall St.
·
Jul 06

How Investors Are Reacting To Quest Diagnostics (DGX) New MRD Test Milestone And Attunio Partnership

Simply Wall St.
·
Jul 04

Quest Diagnostics Inc. Stock Underperforms Wednesday When Compared to Competitors Despite Daily Gains

Dow Jones
·
Jul 02

Quest Diagnostics Inc. Stock Outperforms Competitors on Strong Trading Day

Dow Jones
·
Jun 30

Quest Diagnostics Inc. Stock Underperforms Thursday When Compared to Competitors Despite Daily Gains

Dow Jones
·
Jun 26

Quest Diagnostics’ Haystack MRD test receives New York SDOH approval

TIPRANKS
·
Jun 24

Quest Diagnostics Receives New York State Approval for Haystack Mrd®, Broadening Patient Access to Ctdna Minimal Residual Disease Testing

THOMSON REUTERS
·
Jun 24

Quest Wins New York State Approval for Haystack MRD Ctdna Test

Reuters
·
Jun 24

Quest Diagnostics Inc. Stock Outperforms Competitors On Strong Trading Day

Dow Jones
·
Jun 24

Quest Diagnostics (DGX) Stock Could Be 12.7% Below Fair Value on Testing Growth Narrative

Simply Wall St.
·
Jun 21

Quest Diagnostics Inc. Stock Underperforms Thursday When Compared To Competitors

Dow Jones
·
Jun 19

Health Rounds: Experimental first-in-class heart drug may also help heal kidneys

Reuters
·
Jun 19

Quest study finds 69.5% of multidrug-resistant Klebsiella pneumoniae non-susceptible to top oral UTI antibiotics

Reuters
·
Jun 18

Quest Diagnostics Inc. Stock Outperforms Competitors Despite Losses On The Day

Dow Jones
·
Jun 18

Quest Diagnostics to report Q2 results, host earnings call

Reuters
·
Jun 17

Quest Diagnostics releases 2025 Corporate Responsibility Report

Reuters
·
Jun 16

GeneDx names former Quest executive Mark Gardner as president

Reuters
·
Jun 16